335 related articles for article (PubMed ID: 18056833)
21. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia.
De Deyn PP; Wirshing WC
J Clin Psychiatry; 2001; 62 Suppl 21():19-22. PubMed ID: 11584983
[TBL] [Abstract][Full Text] [Related]
22. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
23. [Neuropsychiatric symptoms of dementia: psychometric aspects of the Dutch Neuropsychiatric Inventory (NPI)].
Kat MG; de Jonghe JF; Aalten P; Kalisvaart CJ; Dröes RM; Verhey FR
Tijdschr Gerontol Geriatr; 2002 Sep; 33(4):150-5. PubMed ID: 12378786
[TBL] [Abstract][Full Text] [Related]
24. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
25. Memantine for behavioral disturbances in frontotemporal dementia: a case series.
Swanberg MM
Alzheimer Dis Assoc Disord; 2007; 21(2):164-6. PubMed ID: 17545743
[TBL] [Abstract][Full Text] [Related]
26. Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia.
Shinno H; Inami Y; Inagaki T; Nakamura Y; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):881-5. PubMed ID: 18243460
[TBL] [Abstract][Full Text] [Related]
27. Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials.
Cheung G; Stapelberg J
N Z Med J; 2011 Jun; 124(1336):39-50. PubMed ID: 21946743
[TBL] [Abstract][Full Text] [Related]
28. Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
Leroi I; Overshott R; Byrne EJ; Daniel E; Burns A
Mov Disord; 2009 Jun; 24(8):1217-21. PubMed ID: 19370737
[TBL] [Abstract][Full Text] [Related]
29. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis.
Livingston G; Katona C
Int J Geriatr Psychiatry; 2004 Oct; 19(10):919-25. PubMed ID: 15449303
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.
Hellweg R; Wirth Y; Janetzky W; Hartmann S
Int J Geriatr Psychiatry; 2012 Jun; 27(6):651-6. PubMed ID: 22513699
[TBL] [Abstract][Full Text] [Related]
31. Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.
Winblad B; Jones RW; Wirth Y; Stöffler A; Möbius HJ
Dement Geriatr Cogn Disord; 2007; 24(1):20-7. PubMed ID: 17496417
[TBL] [Abstract][Full Text] [Related]
32. Successful treatment with Yokukansan for behavioral and psychological symptoms of Parkinsonian dementia.
Kawanabe T; Yoritaka A; Shimura H; Oizumi H; Tanaka S; Hattori N
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Mar; 34(2):284-7. PubMed ID: 19948198
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
34. Memantine enhances autonomy in moderate to severe Alzheimer's disease.
Rive B; Vercelletto M; Damier FD; Cochran J; François C
Int J Geriatr Psychiatry; 2004 May; 19(5):458-64. PubMed ID: 15156547
[TBL] [Abstract][Full Text] [Related]
35. [The clinical relevance of memantine use].
Sobów T
Psychiatr Pol; 2004; 38(2):321-30. PubMed ID: 15307296
[TBL] [Abstract][Full Text] [Related]
36. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease.
Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ
Arch Neurol; 2006 Jan; 63(1):49-54. PubMed ID: 16401736
[TBL] [Abstract][Full Text] [Related]
37. Memantine: pharmacological properties and clinical uses.
Kumar S
Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
[TBL] [Abstract][Full Text] [Related]
38. [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
Kitamura Y; Kudo Y; Imamura T
No To Shinkei; 2006 Jun; 58(6):483-8. PubMed ID: 16856516
[TBL] [Abstract][Full Text] [Related]
39. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia.
Onor ML; Saina M; Trevisiol M; Cristante T; Aguglia E
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):205-9. PubMed ID: 17020789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
